Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Blueprint Medicines

DB:2L9
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2L9
DB
$4B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Blueprint Medicines has significant price volatility in the past 3 months.
2L9 Share Price and Events
7 Day Returns
17.6%
DB:2L9
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-11.4%
DB:2L9
-7.4%
DE Biotechs
-14.2%
DE Market
2L9 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Blueprint Medicines (2L9) 17.6% 25.6% -16% -11.4% 50.2% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • 2L9 underperformed the Biotechs industry which returned -7.4% over the past year.
  • 2L9 outperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
2L9
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Blueprint Medicines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Blueprint Medicines to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Blueprint Medicines.

DB:2L9 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 15 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:2L9
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (2.72%))
1.047
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.05
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.047 * 5.44%)
5.31%

Discounted Cash Flow Calculation for DB:2L9 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Blueprint Medicines is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:2L9 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.31%)
2020 -399.36 Analyst x2 -379.23
2021 -201.73 Analyst x2 -181.91
2022 -114.66 Analyst x2 -98.18
2023 218.12 Analyst x2 177.36
2024 593.22 Analyst x2 458.06
2025 945.03 Est @ 59.3% 692.93
2026 1,336.23 Est @ 41.4% 930.39
2027 1,721.86 Est @ 28.86% 1,138.48
2028 2,067.70 Est @ 20.09% 1,298.24
2029 2,355.99 Est @ 13.94% 1,404.70
Present value of next 10 years cash flows $5,440.00
DB:2L9 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $2,355.99 × (1 + -0.39%) ÷ (5.31% – -0.39%)
$41,190.38
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $41,190.38 ÷ (1 + 5.31%)10
$24,558.68
DB:2L9 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $5,440.00 + $24,558.68
$29,998.68
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $29,998.68 / 54.03
$555.25
DB:2L9 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:2L9 represents 0.89572x of NasdaqGS:BPMC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89572x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 555.25 x 0.89572
€497.35
Value per share (EUR) From above. €497.35
Current discount Discount to share price of €60.04
= -1 x (€60.04 - €497.35) / €497.35
87.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Blueprint Medicines is available for.
Intrinsic value
>50%
Share price is €60.04 vs Future cash flow value of €497.35
Current Discount Checks
For Blueprint Medicines to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Blueprint Medicines's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Blueprint Medicines's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Blueprint Medicines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Blueprint Medicines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2L9 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-7.27
NasdaqGS:BPMC Share Price ** NasdaqGS (2020-04-08) in USD $67.03
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Blueprint Medicines.

DB:2L9 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BPMC Share Price ÷ EPS (both in USD)

= 67.03 ÷ -7.27

-9.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Blueprint Medicines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Blueprint Medicines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Blueprint Medicines's expected growth come at a high price?
Raw Data
DB:2L9 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts
51.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Blueprint Medicines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Blueprint Medicines's assets?
Raw Data
DB:2L9 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $9.42
NasdaqGS:BPMC Share Price * NasdaqGS (2020-04-08) in USD $67.03
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:2L9 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BPMC Share Price ÷ Book Value per Share (both in USD)

= 67.03 ÷ 9.42

7.11x

* Primary Listing of Blueprint Medicines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Blueprint Medicines is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Blueprint Medicines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Blueprint Medicines has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Blueprint Medicines expected to perform in the next 1 to 3 years based on estimates from 15 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
51.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Blueprint Medicines expected to grow at an attractive rate?
  • Blueprint Medicines's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Blueprint Medicines's earnings growth is expected to exceed the Germany market average.
  • Blueprint Medicines's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2L9 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2L9 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 15 Analysts 51.2%
DB:2L9 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 15 Analysts 50.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2L9 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2L9 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,302 436 464 9
2023-12-31 941 109 143 10
2022-12-31 443 -203 -167 15
2021-12-31 170 -436 -379 15
2020-12-31 34 -380 -472 15
2020-04-08
DB:2L9 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 67 -278 -348
2019-09-30 16 -301 -362
2019-06-30 8 -284 -340
2019-03-31 44 -206 -268
2018-12-31 45 -175 -237
2018-09-30 45 -142 -205
2018-06-30 52 -114 -170
2018-03-31 17 -138 -177
2017-12-31 21 -120 -148
2017-09-30 27 -104 -120
2017-06-30 26 -96 -99
2017-03-31 27 -86 -85

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Blueprint Medicines's earnings are expected to grow significantly at over 20% yearly.
  • Blueprint Medicines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2L9 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below

All data from Blueprint Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2L9 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 7.30 11.26 3.27 9.00
2023-12-31 3.36 6.51 1.92 6.00
2022-12-31 -2.80 0.51 -6.01 13.00
2021-12-31 -6.60 -4.46 -8.13 13.00
2020-12-31 -8.79 -7.88 -9.40 13.00
2020-04-08
DB:2L9 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -7.27
2019-09-30 -7.78
2019-06-30 -7.52
2019-03-31 -6.08
2018-12-31 -5.39
2018-09-30 -4.79
2018-06-30 -4.09
2018-03-31 -4.37
2017-12-31 -3.92
2017-09-30 -3.45
2017-06-30 -3.12
2017-03-31 -2.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Blueprint Medicines will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Blueprint Medicines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Blueprint Medicines has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Blueprint Medicines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Blueprint Medicines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Blueprint Medicines does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Blueprint Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Blueprint Medicines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Blueprint Medicines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Blueprint Medicines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2L9 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 66.51 -347.69 96.39
2019-09-30 16.01 -361.69 77.77
2019-06-30 7.97 -340.13 64.16
2019-03-31 44.30 -267.50 54.57
2018-12-31 44.52 -236.64 47.93
2018-09-30 45.12 -205.35 42.38
2018-06-30 52.09 -170.33 37.71
2018-03-31 16.54 -176.69 32.21
2017-12-31 21.43 -148.12 27.99
2017-09-30 27.49 -120.36 24.89
2017-06-30 25.58 -99.49 22.40
2017-03-31 26.76 -84.97 20.26
2016-12-31 27.77 -72.50 19.22
2016-09-30 24.72 -66.81 17.85
2016-06-30 21.98 -62.62 17.18
2016-03-31 17.60 -57.58 16.33
2015-12-31 11.40 -55.92 14.46
2015-09-30 6.77 -56.72 13.79
2015-06-30 3.34 -55.89 11.49
2015-03-31 0.65 -51.62 9.09
2014-12-31 -46.05 7.89
2013-12-31 -23.78 5.07

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Blueprint Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Blueprint Medicines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Blueprint Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Blueprint Medicines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Blueprint Medicines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Blueprint Medicines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Blueprint Medicines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Blueprint Medicines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Blueprint Medicines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Blueprint Medicines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -3.6365581828598E+16x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Blueprint Medicines Company Filings, last reported 3 months ago.

DB:2L9 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 464.36 0.00 483.55
2019-09-30 516.34 0.00 493.44
2019-06-30 592.83 0.00 592.86
2019-03-31 344.21 0.00 415.86
2018-12-31 419.01 0.00 494.01
2018-09-30 489.30 0.28 559.64
2018-06-30 552.93 0.69 613.46
2018-03-31 570.87 1.11 607.33
2017-12-31 623.97 1.52 673.36
2017-09-30 341.24 2.10 390.65
2017-06-30 374.09 2.67 421.01
2017-03-31 188.22 3.25 206.40
2016-12-31 213.08 4.07 214.16
2016-09-30 97.71 4.89 152.54
2016-06-30 112.56 5.71 172.55
2016-03-31 129.66 6.52 191.51
2015-12-31 143.98 7.34 162.71
2015-09-30 158.14 7.87 179.78
2015-06-30 169.59 8.26 193.59
2015-03-31 25.13 8.65 50.30
2014-12-31 35.79 9.04 47.24
2013-12-31 -1.38 2.86 1.99
  • Blueprint Medicines's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (25.3% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Blueprint Medicines has sufficient cash runway for 1.7 years based on current free cash flow.
  • Blueprint Medicines has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 47.4% each year.
X
Financial health checks
We assess Blueprint Medicines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Blueprint Medicines has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Blueprint Medicines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Blueprint Medicines dividends. Estimated to be 0% next year.
If you bought €2,000 of Blueprint Medicines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Blueprint Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Blueprint Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2L9 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 15 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2L9 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Blueprint Medicines has not reported any payouts.
  • Unable to verify if Blueprint Medicines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Blueprint Medicines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Blueprint Medicines has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Blueprint Medicines's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Blueprint Medicines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Blueprint Medicines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Blueprint Medicines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Blueprint Medicines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Albers
COMPENSATION $9,740,799
AGE 48
TENURE AS CEO 5.8 years
CEO Bio

Mr. Jeffrey W. Albers, also known as Jeff, J.D., MBA has been the Chief Executive Officer and President of Blueprint Medicines Corp since July 2014. Mr. Albers has been President of Algeta US at Algeta ASA since January 15, 2012. He works closely with Algeta's senior management as part of the executive management team to enable Algeta's US commercial operations; the plans for which include the phased building of a sales force and a marketing and medical affairs team ahead of the launch of Alpharadin (radium-223 chloride) for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases, pending approval. Prior to Algeta, he served at Genzyme (Sanofi), where he spent seven years in senior commercial and corporate development positions and also served as its Vice President of US Hematology & Oncology Business. In this role, Mr. Albers was P&L responsible for a USD 250 m business that included multiple marketed products along with a pipeline of products to treat hematologic and solid tumor malignancies. He built and led a 135-person team spanning sales, operations, marketing, managed care, pricing and reimbursement, training and medical affairs. He was also involved in evaluating in-licensing opportunities. Mr. Albers played a key role in the successful US launch of Mozobil and integrating Campath and Leukine into the portfolio involving a significant field force restructuring. Prior to Genzyme, he spent five years, from 2000 to 2005 as an Attorney at the law firm Mintz Levin Cohn Ferris Glovsky & Popeo, where he focused on life sciences transactional work. He has prior experience as a sales representative for Pfizer, Inc. He has been a Director of Blueprint Medicines Corp since July 2014 and Magenta Therapeutics, Inc. since July 2017. He holds a B.Sc. in Marketing from Indiana University and a law degree (J.D.) and MBA degree from Georgetown University (Washington, DC).

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Blueprint Medicines management team in years:

3.4
Average Tenure
47.5
Average Age
  • The tenure for the Blueprint Medicines management team is about average.
Management Team

Jeff Albers

TITLE
CEO, President & Director
COMPENSATION
$10M
AGE
48
TENURE
5.8 yrs

Alexis Borisy

TITLE
Co-Founder & Director
COMPENSATION
$369K
AGE
47

Mike Landsittel

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
47
TENURE
4.2 yrs

Tracey Mccain

TITLE
Executive VP
COMPENSATION
$3M
AGE
51
TENURE
3.6 yrs

Andy Boral

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
56
TENURE
5.2 yrs

Christy Rossi

TITLE
Chief Commercial Officer
COMPENSATION
$4M
AGE
43
TENURE
1.5 yrs

Kate Haviland

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
43
TENURE
1.3 yrs

Ariel Hurley

TITLE
Principal Accounting Officer
AGE
45
TENURE
1.1 yrs

Chris Murray

TITLE
Senior Vice President of Technical Operations
COMPENSATION
$4M
AGE
56
TENURE
2.5 yrs

Marion Dorsch

TITLE
Chief Scientific Officer
COMPENSATION
$3M
AGE
54
TENURE
3.4 yrs
Board of Directors Tenure

Average tenure and age of the Blueprint Medicines board of directors in years:

5.8
Average Tenure
61
Average Age
  • The tenure for the Blueprint Medicines board of directors is about average.
Board of Directors

Dan Lynch

TITLE
Independent Chairman of the Board
COMPENSATION
$398K
AGE
61
TENURE
7.6 yrs

Jeff Albers

TITLE
CEO, President & Director
COMPENSATION
$10M
AGE
48
TENURE
5.8 yrs

Alexis Borisy

TITLE
Co-Founder & Director
COMPENSATION
$369K
AGE
47
TENURE
9 yrs

George Demetri

TITLE
Member of Scientific Advisory Board & Independent Director
COMPENSATION
$377K
AGE
62
TENURE
5.3 yrs

Charlie Rowland

TITLE
Independent Director
COMPENSATION
$384K
AGE
61
TENURE
5.1 yrs

Nick Lydon

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$397K
AGE
62

Brian Druker

TITLE
Member of Scientific Advisory Board
AGE
63

Scott Lowe

TITLE
Member of Scientific Advisory Board

Charles Sawyers

TITLE
Member of Scientific Advisory Board
AGE
60

Giulio Draetta

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • Blueprint Medicines individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Mar 20 Sell Ariel Hurley Individual 09. Mar 20 09. Mar 20 -253 €45.44 €-11,496
11. Mar 20 Sell Tracey Mccain Individual 09. Mar 20 09. Mar 20 -617 €45.47 €-28,056
11. Mar 20 Sell Christopher Murray Individual 09. Mar 20 09. Mar 20 -402 €45.44 €-18,266
11. Mar 20 Sell Christina Rossi Individual 09. Mar 20 09. Mar 20 -135 €45.45 €-6,136
11. Mar 20 Sell Jeffrey Albers Individual 09. Mar 20 09. Mar 20 -2,277 €45.46 €-103,520
11. Mar 20 Sell Anthony Boral Individual 09. Mar 20 09. Mar 20 -536 €45.46 €-24,368
11. Mar 20 Sell Debra Durso-Bumpus Individual 09. Mar 20 09. Mar 20 -432 €45.44 €-19,629
11. Mar 20 Sell Kathryn Haviland Individual 09. Mar 20 09. Mar 20 -671 €45.47 €-30,512
11. Mar 20 Sell Marion Dorsch Individual 09. Mar 20 09. Mar 20 -536 €45.48 €-24,378
11. Mar 20 Sell Michael Landsittel Individual 09. Mar 20 09. Mar 20 -400 €45.46 €-18,185
X
Management checks
We assess Blueprint Medicines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Blueprint Medicines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Details
Name: Blueprint Medicines Corporation
2L9
Exchange: DB
Founded: 2008
$3,242,328,077
54,027,009
Website: http://www.blueprintmedicines.com
Address: Blueprint Medicines Corporation
45 Sidney Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BPMC Common Stock Nasdaq Global Select US USD 30. Apr 2015
DB 2L9 Common Stock Deutsche Boerse AG DE EUR 30. Apr 2015
LSE 0HOJ Common Stock London Stock Exchange GB USD 30. Apr 2015
Number of employees
Current staff
Staff numbers
383
Blueprint Medicines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:39
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/06
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.